← Leaderboards
David Herman
Mayo Clinic
$471,954
Attributed
$471,954
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $98.2K · FY2005–08$100K$75K$50K$25K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$471,954 · 1
By mechanism
U10$471,954 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Beta Antiadrenergic Agent”
- Christopher M O'Connor · Duke University$18,508,673
- Michael A Kass · Washington University$9,081,282
- Bruce M Psaty · University Of Washington$5,047,845
- Kenneth Allen Holroyd · Ohio University Athens$2,665,090
- Jeffrey H Silverstein · Mount Sinai School Of Medicine Of Nyu$2,655,974
- Susan Heckbert · University Of Washington$2,562,214
Research focus
Beta Antiadrenergic AgentManualsClinicDrug Adverse EffectMioticNumbersOcular HypertensionDesignPerformanceEnrollmentProceduresDisease /Disorder Proneness /RiskResearch PersonnelStatistics /BiometryHypertension TreatmentDocumentationAbstractingIntraocular PressureLongitudinal Human StudyMass ScreeningMedical ComplicationOptic DiskPilocarpinePrognosis
Grant awards (5)
OCULAR HYPERTENSION TREATMENT STUDY (OHTS)$98,246
U10 · FY2008 · EY · contact PI
OCULAR HYPERTENSION TREATMENT STUDY (OHTS)$96,290
U10 · FY2007 · EY · contact PI
OCULAR HYPERTENSION TREATMENT STUDY (OHTS)$94,396
U10 · FY2006 · EY · contact PI
OCULAR HYPERTENSION TREATMENT STUDY (OHTS)$92,263
U10 · FY2005 · EY
OCULAR HYPERTENSION TREATMENT STUDY (OHTS)$90,759
U10 · FY2004 · EY